Clinical trial • Phase I • Oncology
MAQ-001 for Metastatic melanoma | Lung cancer | Renal cell carcinoma | Hodgkin lymphoma | Microsatellite instability-high colon cancer | Hepatocellular carcinoma | Gastric cancer
Phase I trial of MAQ-001 for Metastatic melanoma | Lung cancer | Renal cell carcinoma | Hodgkin lymphoma | Microsatellite instability-high colon cancer |…
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Metastatic melanoma | Lung cancer | Renal cell carcinoma | Hodgkin lymphoma | Microsatellite instability-high colon cancer | Hepatocellular carcinoma | Gastric cancer
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 30-10-2023
- First CTIS Authorization Date
- 19-02-2024
Trial design
None/Not specified-controlled Phase I trial across 4 sites in France.
- Comparator
- None/Not specified
- Target Sample Size
- 30
Recruitment
- Planned Sample Size
- 30
- Recruitment Window Months
- 49
Geography
- Total Number Of Sites
- 4
- Total Number Of Participants
- 30
France
- Earliest CTIS Part Ii Submission Date
- 18-12-2023
- Latest Decision Or Authorization Date
- 18-03-2026
- Processing Time Days
- 821
- Number Of Sites
- 4
- Number Of Participants
- 30
Sites
- Site Name
- Centre De Lutte Contre Le Cancer Eugene Marquis
- Department Name
- Oncologie medicale
- Contact Person Name
- Thibault De La Motte Rouge
- Contact Person Email
- t.delamotterouge@rennes.unicancer.fr
- Site Name
- Institut Universitaire Du Cancer Toulouse-Oncopole
- Department Name
- Oncologie medicale
- Contact Person Name
- Carlos GOMEZ-ROCCA
- Contact Person Email
- gomezroca.carlos@iuct-oncopole.fr
- Site Name
- Centre Leon Berard
- Department Name
- Oncologie medicale
- Contact Person Name
- Philippe CASSIER
- Contact Person Email
- Philippe.cassier@lyon.unicancer.fr
- Site Name
- Institut Gustave Roussy
- Department Name
- DITEP
- Contact Person Name
- Anas GAZZAH
- Contact Person Email
- anas.gazzah@gustaveroussy.fr
Sponsor
Primary sponsor
- Full Name
- MabQuest Therapeutics S.A.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Switzerland
Investigational products
- Investigational Product Name
- MAQ-001
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)